A-139 B2 involvement as a surrogate marker for a rapid and sustained response to treatment with mogamulizumab in mycosis fungoides and Sézary syndrome.

Authors :: Stadler, R.
Angela, Y.
Protzmann, J.
Bielefeld, A.
Schaper-Gerhardt, K.
Gutzmer, R.
Source :: European Journal of Cancer. 2024 Supplement 2, Vol. 211, pN.PAG-N.PAG. 1p.
Publication Year :: 2024

Subjects :: *THERAPEUTIC use of monoclonal antibodies
*SEZARY syndrome
*MYCOSIS fungoides
*TREATMENT effectiveness
*CONFERENCES & conventions
*BIOMARKERS

Full Text Access

Tools